Service d'ORL Pédiatrique, Necker Hospital, AP-HP, Université Paris 5, Paris, France.
Pediatr Infect Dis J. 2012 Feb;31(2):154-8. doi: 10.1097/INF.0b013e3182357c8d.
Before 7-valent pneumococcal conjugate vaccine (PCV7) implementation in France, several studies had described the microbiology of acute otitis media (AOM) treatment failures. The causative pathogens were Streptococcus pneumoniae (Sp) followed by nontypable Haemophilus influenzae (NTHi). The aim of this study was to describe the epidemiology of pathogens involved in AOM treatment failures or recurrences.
This French multicentric prospective study enrolled 143 children with AOM treatment failure between 2007 and 2009 observed by 8 ear, nose, and throat specialists. Failure was defined as the persistence of AOM symptoms after at least 48 hours of antibiotic therapy or their recurrence within 4 days after the end of treatment. Standardized history and physical examination findings were recorded, and culture of middle ear fluid (MEF) was obtained.
Mean age was 16.9 ± 9.9 months (median, 13.7). Eighty-eight percent of children had received more than 1 dose of PCV7, and 70.6% attended day care. The most common antibiotic used at the time of treatment failure or recurrence was a combination of amoxicillin and clavulanate (51.1%). Bacteriologic sampling demonstrated that in 35% of cases (n=50), no otopathogen was cultured at the time of treatment failure or recurrence. Similar proportions of Sp and NTHi were observed in the 86 patients (60.1%) from whom only a single species was recovered from MEF (46.5% for Sp, n=40 and 45.3% for NTHi, n=39). Among Sp strains, 4.4% were penicillin susceptible, 77.8% were penicillin intermediate, and 17.8% were fully penicillin resistant, and serotype 19A represented 84.5% of all serotypes detected. Among NTHi isolates, 15.5% (n=7) were β-lactamase-producing strains (including 2 strains with only this mechanism of resistance), and strains with reduced susceptibility by changes in protein binding to penicillin (β-lactamase-negative ampicillin resistant strains) represented 35.5% of cases. Among the 50 sterile MEF samples, polymerase chain reaction was performed in 32, of which 4 were positive for HI, 3 for Sp, and 3 for both.
Among children with AOM treatment failures in France, Sp and NTHi were equally distributed; 19A was the main Sp serotype, and the main resistance mechanism for NTHi was β-lactamase-negative ampicillin resistance.
在法国实施 7 价肺炎球菌结合疫苗(PCV7)之前,已有多项研究描述了急性中耳炎(AOM)治疗失败的微生物学特征。导致感染的病原体主要为肺炎链球菌(Sp),其次是非典型流感嗜血杆菌(NTHi)。本研究旨在描述 AOM 治疗失败或复发相关病原体的流行病学特征。
本项法国多中心前瞻性研究纳入了 2007 年至 2009 年间 8 位耳鼻喉科专家观察到的 143 例 AOM 治疗失败的患儿。失败的定义为抗生素治疗至少 48 小时后 AOM 症状持续存在或治疗结束后 4 天内复发。记录标准化的病史和体格检查结果,并进行中耳液(MEF)培养。
患儿平均年龄为 16.9±9.9 个月(中位数为 13.7 个月)。88%的患儿接受过≥1 剂 PCV7 接种,70.6%患儿曾入托。治疗失败或复发时最常使用的抗生素为阿莫西林-克拉维酸(51.1%)。细菌学采样显示,35%(n=50)的患儿在治疗失败或复发时未培养出病原体。86 例仅从 MEF 中分离出单一病原体的患儿中,Sp 和 NTHi 的比例相似(Sp 为 46.5%,n=40;NTHi 为 45.3%,n=39)。Sp 菌株中,4.4%为青霉素敏感株,77.8%为青霉素中介株,17.8%为完全耐青霉素株,血清型 19A 占所有检测到的血清型的 84.5%。NTHi 分离株中,15.5%(n=7)为产β-内酰胺酶菌株(包括 2 株仅有此耐药机制的菌株),对青霉素蛋白结合改变敏感降低的菌株(β-内酰胺酶阴性耐氨苄西林菌株)占 35.5%。在 50 例无菌 MEF 样本中,32 例进行了聚合酶链反应,其中 HI 阳性 4 例,Sp 阳性 3 例,两者均阳性 3 例。
在法国 AOM 治疗失败的患儿中,Sp 和 NTHi 分布比例相同;19A 是主要的 Sp 血清型,NTHi 的主要耐药机制为β-内酰胺酶阴性耐氨苄西林。